Company

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
BayerETR: BAYN

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian 50 mg tablets, under the brand name Sunharbo — the first…

Charles River to Acquire Frontage's Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases
Gilead SciencesLEO Pharma

Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases

Junshi Biosciences' Mindewei Receives Full Approval in China
COVID-19HKG: 1877

Junshi Biosciences’ Mindewei Receives Full Approval in China

Ucello Biotech's UC101 Receives FDA IND Clearance for Anti-CD19 Therapy
CAR-TClinical trial approval / initiation

Ucello Biotech’s UC101 Receives FDA IND Clearance for Anti-CD19 Therapy

Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio
Harbour BioMedHKG: 2142

Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio

Show More